ReviewOrphanet journal of rare diseases2019
Current challenges in the management of patients with sickle cell disease - A report of the Italian experience.
Review in Orphanet journal of rare diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Transfusion strategies in thalassemia and sickle cell disease SITE-SIMTI-SIdEM Good Practice.Blood transfusion = Trasfusione del sangueGuideline
- Frequency of Alloimmunization in Patients on Regular Blood Transfusion in Riyadh, Saudi Arabia: A Multicenter Retrospective Study.Journal of clinical medicine · 2026Article
- The Heterogeneous Global Burden of Hemoglobinopathies Among Women of Childbearing Age, 1990-2021, with Projection to 2030.International journal of women's health · 2026Article
- Oxford Hip and Shoulder Scores as Potential Tools for the Early Detection of Avascular Necrosis in Apparently Unaffected Sites in Sickle Cell Disease: Results from a Prospective Cohort Study.Journal of clinical medicine · 2025Article
- Breaking barriers: Enhancing hospital support for sickle cell disease management.Journal of public health research · 2025Article
- Underlying disease is the main risk factor in post-splenectomy complication risk: Data from a national database.British journal of haematology · 2025Article
- The phenotypes of sickle cell disease: strategies to aid the identification of undiagnosed patients in the Italian landscape.Italian journal of pediatrics · 2025Review
- Thalassemias and Sickle Cell Diseases in Pregnancy: SITE Good Practice.Journal of clinical medicine · 2025Article
- Screening for sickle cell disease by point-of-care tests in Italy: pilot study on 1000 at risk children.European journal of pediatrics · 2025Article
- Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy.PharmacoEconomics - open · 2025Article
- Sickle cell disease: suspect, check, diagnose-practical tips for non-SCD experts to suspect and diagnose SCD in low-prevalence European settings.Frontiers in medicine · 2025Review
- Erythroferrone-Driven Regulation of Hepcidin and Iron Levels in Polytransfused Sickle Cell Anaemia Patients: A Prospective Study.BioMed research international · 2025Article
- Long-term outcomes of avascular necrosis in sickle cell disease using joint-specific patient-reported outcome measures: Results from a multicentre study.British journal of haematology · 2025Article
- End Organ Affection in Sickle Cell Disease.Cells · 2024Review
- Absence of blood donors' anti-SARS-CoV-2 antibodies in pre-storage leukoreduced red blood cell units indicates no role of passive immunity for blood recipients.Annals of hematology · 2024Article
- Management of the Sickle Cell Trait: An Opinion by Expert Panel Members.Journal of clinical medicine · 2023Review
- Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy.Journal of clinical medicine · 2022Article
- Environmental Factors in Northern Italy and Sickle Cell Disease Acute Complications: A Multicentric Study.Children (Basel, Switzerland) · 2022Article
- Screening and diagnosis of hemoglobinopathies in Germany: Current state and future perspectives.Scientific reports · 2022Article
- Rare paediatric case of agenesis of the vermiform appendix, ileal duplication and sickle cell disease.BMJ case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) is an inherited red blood cell disorder caused by a structural abnormality of hemoglobin called sickle hemoglobin (HbS). Clinical manifestations of SCD are mainly characterized by chronic hemolysis and acute vaso-occlusive crisis, which are responsible for severe acute and chronic organ damage. SCD is widespread in sub-Saharan Africa, in the Middle East, Indian subcontinent, and some Mediterranean regions. With voluntary population migrations, people harboring the HbS gene have spread globally. In 2006, the World Health Organization recognized hemoglobinopathies, including SCD, as a global public health problem and urged national health systems worldwide to design and establish programs for the prevention and management of SCD. Herein we describe the historical experience of the network of hemoglobinopathy centers and their approach to SCD in Italy, a country where hemoglobinopathies have a high prevalence and where SCD, associated with different genotypes including ß-thalassemia, is present in the native population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.